SOLIGENIX, INC. (SNGX) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues:
Public Health Solutions	0.9	0.8	2.2	3.4	4.2
Specialized BioTherapeutics	0.0		0.1	1.2	1.1
BioTherapeutics						0.7		0.0
Other						4.7		8.8
Total revenues [+]	0.9	0.8	2.4	4.6	5.2	5.4	10.4	8.8
Contracts							10.4	8.6
Grants								0.1
Revenue growth [+]	15.1%	-65.1%	-49.0%	-11.7%	-3.5%	-48.0%	19.2%	24.5%
Public Health Solutions	11.2%	-63.2%	-34.1%	-18.2%
Specialized BioTherapeutics			-90.4%	13.2%
BioTherapeutics								-95.1%
Vaccines/BioDefense						-54.5%	19.4%	29.6%
Cost of goods sold	0.6	0.7	1.8	3.6	4.6	4.3	8.4	6.9
Gross profit	0.4	0.1	0.5	1.1	0.6	1.1	2.0	1.9
Gross margin	42.0%	11.6%	22.8%	22.9%	12.3%	20.7%	19.3%	21.5%
Selling, general and administrative [+]	6.7	5.0	4.3	3.5	3.0	3.2	3.4	3.6
General and administrative	6.7	5.0	4.3	3.5	3.0	3.2	3.4	3.6
Research and development	7.9	8.2	9.8	8.1	6.8	5.5	4.3	5.4
Other operating expenses			5.0			0.0
EBITDA [+]	-14.2	-13.1	-18.5	-10.5	-9.0	-7.5	-5.6	-6.9
EBITDA growth	8.8%	-29.5%	76.6%	16.3%	20.3%	33.4%	-18.1%	5.3%
EBITDA margin	-1498.0%	-1585.0%	-785.1%	-226.5%	-172.0%	-138.0%	-53.8%	-78.3%
Depreciation	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
EBITA	-14.2	-13.1	-18.6	-10.5	-9.0	-7.5	-5.6	-6.9
EBITA margin	-1500.6%	-1589.2%	-787.7%	-227.1%	-172.3%	-138.3%	-54.0%	-78.6%
Amortization of intangibles				0.0	0.0	0.1	0.1	0.2
EBIT [+]	-14.2	-13.1	-18.6	-10.5	-9.1	-7.6	-5.7	-7.1
EBIT growth	8.7%	-29.5%	76.3%	16.4%	19.8%	32.5%	-19.7%	5.2%
EBIT margin	-1500.6%	-1589.2%	-787.7%	-227.7%	-172.8%	-139.2%	-54.6%	-81.1%
Non-recurring items [+]						0.0
Unusual expense						0.0
Interest expense, net [+]	0.8	0.9	0.0	-0.1	-0.2			0.0
Interest expense	0.8	0.9	0.0					0.0
Interest income				0.1	0.2
Other income (expense), net [+]	0.1	0.6	0.1	0.4	0.0	0.0	1.9	-1.2
Litigation settlement							0.4
Gain (loss) on debt retirement		0.4
Unrealized gain/loss on derivatives							1.5
Gain (loss) on foreign currency transactions	0.0	0.0
Change in fair value of warrants							1.5	-1.2
Other non-operating gains/losses							0.0
Other	0.0	0.0	0.1				0.0
Pre-tax income	-15.0	-13.4	-18.5	-10.0	-8.9	-7.6	-3.8	-8.3
Income taxes	-1.2	-0.9	-0.8	-0.6	0.0	-0.4	-0.5	-0.5
Tax rate	7.7%	6.4%	4.5%	6.1%	0.0%	5.5%	14.0%	5.9%
Net income	-13.8	-12.6	-17.7	-9.4	-8.9	-7.1	-3.2	-7.8
Net margin	-1454.1%	-1522.7%	-749.7%	-202.1%	-169.8%	-131.6%	-31.1%	-89.3%

Basic EPS [+]	($4.81)	($4.69)	($0.64)	($0.48)	($0.68)	($1.16)	($0.93)	($3.00)
Growth	2.4%	629.0%	33.3%	-28.5%	-41.9%	24.8%	-69.0%	824.5%
Diluted EPS [+]	($4.81)	($4.69)	($0.64)	($0.48)	($0.68)	($1.16)	($0.91)	($3.00)
Growth	2.4%	629.0%	33.3%	-28.5%	-41.9%	28.4%	-69.9%	956.5%

Shares outstanding (basic) [+]	2.9	2.7	27.5	19.4	13.2	6.1	3.5	2.6
Growth	7.3%	-90.3%	41.9%	47.0%	114.5%	76.5%	33.6%	-87.4%
Shares outstanding (diluted) [+]	2.9	2.7	27.5	19.4	13.2	6.1	3.6	2.6
Growth	7.3%	-90.3%	41.9%	47.0%	114.5%	71.5%	37.5%	-88.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.